About 1.5 million Australians may be currently exposed to carcinogens in their jobs. This estimate is based on European data and we need Australian information in order to direct future Australian research, policy and practice. The project will survey 5000 Australian workers to estimate the exposure to up to 53 prioity occupational chemicals. This will provide a sound basis for estimating the occupational risk of cancers for Australian workers and determining how to decrease the number of cancer ....About 1.5 million Australians may be currently exposed to carcinogens in their jobs. This estimate is based on European data and we need Australian information in order to direct future Australian research, policy and practice. The project will survey 5000 Australian workers to estimate the exposure to up to 53 prioity occupational chemicals. This will provide a sound basis for estimating the occupational risk of cancers for Australian workers and determining how to decrease the number of cancers caused by work.Read moreRead less
The Role Of Interleukin (IL)-27 In The Endogenous Anti-tumour Immune Response And The Use Of An IL-27 Agonist As A Cancer Therapeutic.
Funder
National Health and Medical Research Council
Funding Amount
$473,960.00
Summary
Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new ....Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new therapeutic strategy for some human cancers.Read moreRead less